No abstract

To explore the prevalence of SARS-CoV2 infection in the psychiatric emergency room setting. A Cross-sectional retrospective chart review was used to determine the point-prevalence of SARS-CoV2 infection and the characteristics of those infected. Of the patients tested for SARS-CoV2, 23/1057 (2.2%) were positive. Most of these patients were homeless (living on the street) or came from congregate living settings. The high percentage of SARS-CoV2 positive psychiatric patients coming from congregate living settings stresses the importance of asymptomatic screening in this vulnerable population.

El estudio tuvo como objetivo general, determinar las diferencias que existen en las habilidades directivas en un contexto de emergencia sanitaria COVID-19 según la percepción de los docentes en instituciones educativas de la UGEL 01, Red 14 de Lima Sur - Perú. El enfoque de la investigación fue cuantitativo, diseño no experimental, nivel descriptivo comparativo; la muestra estuvo constituida por 127 docentes de las instituciones educativas en las cuales se realizó la investigación; el instrumento empleado fue un formulario Google, estructurado por 20 reactivos, en la escala Likert; lo que permitió recopilar información sobre la percepción de los docentes. A través de la evaluación por parejas de las habilidades directivas se muestra que todas corroboran diferencias a excepción del par de habilidades personales y grupales en donde sus niveles de prevalencias son similares. Se concluye que existen diferencias significativas en las habilidades directivas en un contexto de emergencia sanitaria COVID-19.

Objectives: Effective treatment with biologic DMARDs poses a significant economic burden. Recent subgroup analyses showed improved efficacy for abatacept in serum anti-citrullinated protein antibody (ACPA)-positive patients, with increasing efficacy across ACPA quartile levels. The aim of the study was to evaluate the cost per response of abatacept relative to adalimumab in ACPA-positive patients with RA from the Italian societal perspective. MethOds: A decision tree was designed to compare the cost per response of abatacept with adalimumab in a cohort of 1000 ACPA-positive patients over 2 years. Clinical inputs were based on the Abatacept versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate AMPLE trial, and response was based on ACR20/50/70/90 and HAQ-DI. Unit costs for direct medical costs of AEs were based on Italian tariffs for diseaserelated groups and the ex-manufacturer's price, including mandatory reductions, payback and transparent discounts for drugs. Societal costs included patient costs, indirect costs of work absence and early retirement, according to HAQ functional capacity categories. Results: Cost per response in ACPA-positive patients in Italy favoured abatacept compared with adalimumab (-€ 154 for ACR20, -€ 6,426 considering ACR90 and -€ 281 for HAQ-DI). Cost per remission favoured abatacept in ACPA-positive patients with a cost reduction per CDAI and SDAI equal to € 744 and € 1,310 respectively. Abatacept was consistently favoured in ACPA-Q4 patients across all outcomes in Italy. cOnclusiOns: The cost per selected outcome in ACPA-positive patients favoured SC abatacept compared with SC adalimumab. The costs per all outcomes were lower for SC abatacept than SC adalimumab in ACPA-Q4 patients in Italy. Cost savings were greater when more stringent response criteria were applied and also with increasing ACPA levels, which could lead to a lower overall healthcare budget impact with abatacept compared with adalimumab in Italy.